Search

Displaying results 2211 - 2220 of 5900 in total
  1. Drug

    Influenza A virus A/Guangdong-Maonan/SWL1536/2019 CNIC-1909 (H1N1) antigen (UV, formaldehyde inactivated)

    go.drugbank.com/drugs/DB15714
    ApprovedWithdrawn

    that it was previously exposed to. … Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen

  2. Drug

    Influenza B virus B/Phuket/3073/2013 BVR-1B antigen (formaldehyde inactivated)

    go.drugbank.com/drugs/DB15788
    ApprovedInvestigationalWithdrawn

    that it was previously exposed to. … Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen

  3. Drug

    Lumefantrine co-artemether

    go.drugbank.com/drugs/DB13085
    ApprovedInvestigationalWithdrawn

    falciparum malaria that is resistant to other antimalarials. … Lumefantrine Co-Artemether (Riamet) has been investigated for the treatment of Malaria, Malaria, Falciparum, Malaria in Pregnancy, Uncomplicated Malaria, and Uncomplicated Knowlesi Malaria.

    Synonyms: Lumefantrine co-artemether
  4. Drug

    Rilonacept

    go.drugbank.com/drugs/DB06372
    ApprovedInvestigational

    Rilonacept is a dimeric fusion protein consisting of portions of IL-1R and the IL-1R accessory protein linked to the Fc portion of immunoglobulin G1.

  5. Drug

    Mefloquine

    go.drugbank.com/drugs/DB00358
    Approved

    The 2020 World Health Organization malaria report indicates a 60% decrease in the global malaria fatality rate between 2000 to 2019. … risk for malaria are those in disease naïve populations, children under age 5, refugees in Central and Eastern Africa, nonimmune civilian and military travelers, pregnant women, and immigrants traveling to

  6. Drug

    Pegunigalsidase alfa

    go.drugbank.com/drugs/DB14992
    ApprovedInvestigational

    [A259347,A259352] In May 2023, the EMA granted marketing authorization to pegunigalsidase alfa in the European Union (EU) for the treatment of adult patients with Fabry disease. … Furthermore, the pegylation of pegunigalsidase alfa promotes higher stability and a longer half-life, allowing it to reach target organs with a lower dose and frequency of administration.

  7. Drug

    Dalfampridine

    go.drugbank.com/drugs/DB06637
    ApprovedInvestigational

    Dalfampridine is a potassium channel blocker used to help multiple sclerosis patients walk. This is the first drug that was specifically approved to help with mobility in these patients.

  8. Drug

    Tezepelumab

    go.drugbank.com/drugs/DB15090
    ApprovedInvestigational

    [A243769] Conversely, tezepelumab, which targets the upstream master regulator TSLP, has the potential to be effective across asthma endotypes. … existing asthma treatments such as [omalizumab], [mepolizumab], [reslizumab], [benralizumab], and [dupilumab] act on specific downstream mediators of the inflammatory response, they are mostly limited to

  9. Drug

    Ecallantide

    go.drugbank.com/drugs/DB05311
    Approved

    The amino acid sequence of two compounds differ by seven amino acids [L1458]. … Apart from its FDA and EMA indication, ecallantide has been used off label in the management of nonhistaminergic angioedema, not due to HAE [A32017].

  10. Drug

    Pancrelipase lipase

    go.drugbank.com/drugs/DB13147
    ApprovedInvestigational

    Pancrelipase, in general, is composed of a mixture of pancreatic enzymes which include amylases, lipases, and proteases. These enzymes are extracted from porcine pancreatic glands. The pancrelipase lipase is an enzyme secreted by the pan...